Clocortolone pivalate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413033

CAS#: 34097-16-0 (pivalate)

Description: Clocortolone pivalate is topical, anti-inflammatory glucocorticoid.


Chemical Structure

img
Clocortolone pivalate
CAS# 34097-16-0 (pivalate)

Theoretical Analysis

MedKoo Cat#: 413033
Name: Clocortolone pivalate
CAS#: 34097-16-0 (pivalate)
Chemical Formula: C27H36ClFO5
Exact Mass: 494.22
Molecular Weight: 495.030
Elemental Analysis: C, 65.51; H, 7.33; Cl, 7.16; F, 3.84; O, 16.16

Price and Availability

Size Price Availability Quantity
200mg USD 1200 2 Weeks
Bulk inquiry

Related CAS #: 4258-85-9 (acetate)   34097-16-0 (pivalate)   4891-71-8 (caproate)   4828-27-7 (free base)  

Synonym: Clocortolone pivalate; SH863; SH-863; SH 863

IUPAC/Chemical Name: 9-Chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-pivalate

InChi Key: SXYZQZLHAIHKKY-GSTUPEFVSA-N

InChi Code: InChI=1S/C27H36ClFO5/c1-14-9-16-17-11-19(29)18-10-15(30)7-8-26(18,6)27(17,28)21(32)12-25(16,5)22(14)20(31)13-34-23(33)24(2,3)4/h7-8,10,14,16-17,19,21-22,32H,9,11-13H2,1-6H3/t14-,16+,17+,19+,21+,22-,25+,26+,27+/m1/s1

SMILES Code: C[C@@]12[C@@H](C(COC(C(C)(C)C)=O)=O)[C@H](C)C[C@@]1([H])[C@]3([H])C[C@H](F)C4=CC(C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C2)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 495.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Clocortolone Pivalate. 2021 Jan 18. PMID: 29999716.


2: Kircik LH. Clocortolone pivalate: a topical corticosteroid with a unique structure. J Drugs Dermatol. 2013 Feb;12(2):s3-4. PMID: 23377404.


3: Torok HM, Maas-Irslinger R, Slayton RM. Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis. 2003 Aug;72(2):161-6. PMID: 12953943.


4: Singh S, Mann BK. Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review. Clin Cosmet Investig Dermatol. 2012;5:61-8. doi: 10.2147/CCID.S23227. Epub 2012 Jun 22. PMID: 22791998; PMCID: PMC3393117.


5: Nierman MM. Safety and efficacy of clocortolone pivalate 0.1 percent cream in the treatment of atopic dermatitis, contact dermatitis, and seborrheic dermatitis. Cutis. 1981 Jun;27(6):670-1. PMID: 6453703.


6: Del Rosso JQ, Kircik L. A Comprehensive Review of Clocortolone Pivalate 0.1% Cream: Structural Development, Formulation Characteristics, and Studies Supporting Treatment of Corticosteroid-responsive Dermatoses. J Clin Aesthet Dermatol. 2012 Jul;5(7):20-4. PMID: 22798972; PMCID: PMC3396454.


7: Conde JF, Kaur M, Fleischer AB Jr, Tusa MG, Camacho F, Feldman SR. Adherence to clocortolone pivalate cream 0.1% in a pediatric population with atopic dermatitis. Cutis. 2008 May;81(5):435-41. PMID: 18543596.


8: Dey KK, Gayen S, Ghosh M. Understanding the correlation between structure and dynamics of clocortolone pivalate by solid state NMR measurement. RSC Adv. 2020 Jan 27;10(8):4310-4321. doi: 10.1039/c9ra09866f. PMID: 35495240; PMCID: PMC9049206.


9: Kircik LH, Del Rosso JQ. The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol. 2012 Oct;11(10):1194-8. PMID: 23134984.


10: Del Rosso JQ, Kircik LH. Transitioning from brand to generic with topical products and the importance of maintaining the formulation and therapeutic profiles of the original product: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol. 2014 Jul;13(7):s77-83. PMID: 25007376.


11: Rosenthal AL. Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8. PMID: 6986236.


12: Del Rosso JQ, Kircik LH. The role of a midpotency topical corticosteroid and the clinical relevance of formulation characteristics in the management of commonly encountered eczematous and inflammatory dermatoses in adults and children: focus on the pharmacologic properties of clocortolone pivalate 0.1% cream. J Drugs Dermatol. 2013 Feb;12(2):s5-s10. PMID: 23377405.


13: Xu W, Jia X, Liu W, Zhang X, Chen Y, Zhou L, You S. Identification and characterization of three impurities in clocortolone pivalate. J Pharm Biomed Anal. 2012 Mar 25;62:167-71. doi: 10.1016/j.jpba.2011.11.021. Epub 2011 Dec 8. PMID: 22264563.


14: Kircik LH. A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay. J Drugs Dermatol. 2014 May;13(5):582-5. PMID: 24809882.


15: Heinke E. Behandlung von Erkrankungen der Kopfhaut mit Crino-KABAN [Treatment of diseases of the scalp by Crino-Kaban]. Fortschr Med. 1974 Aug 8;92(22):915-6. German. PMID: 4278481.


16: A new topical corticosteroid. Med Lett Drugs Ther. 1982 Nov 26;24(623):103-4. PMID: 7144689.